Cantor Fitzgerald Reiterates Overweight on Curis
$CRIS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald analyst Li Watsek reiterates Curis (NASDAQ:CRIS) with a Overweight.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2023 | $26.00 | Buy | Truist |
| 4/4/2022 | Outperform → Mkt Perform | Raymond James | |
| 10/13/2021 | $15.00 | Outperform | Raymond James |
LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel
LEXINGTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries. He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio
LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024. "We continue to make excellent progress across our clinical programs. We are especially excited about the recent R/R PCNSL data released in September which continue to demonstrate the activity of emavusertib in c
LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast
LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 2,398,414 shares of common stock. The unregistered warrants to be issued
LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast
EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024. Operational Highlights TakeAim Lymphoma In July 2024, emavusertib was granted Orphan Drug Designation (ODD) by the European Commission (EC) for the treatment of patients with pr
LEXINGTON, Mass., July 25, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast
Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00
Raymond James downgraded Curis from Outperform to Mkt Perform
Raymond James initiated coverage of Curis with a rating of Outperform and set a new price target of $15.00
Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. Nanoviricides (AMEX:NNVC) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. TransCode Therapeutics (N
Truist Securities analyst Robyn Karnauskas maintains Curis (NASDAQ:CRIS) with a Buy and maintains $26 price target.
HC Wainwright & Co. analyst Edward White reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $26 price target.
SC 13G/A - CURIS INC (0001108205) (Subject)
SC 13G - CURIS INC (0001108205) (Subject)
SC 13G - CURIS INC (0001108205) (Subject)
10-Q - CURIS INC (0001108205) (Filer)
8-K - CURIS INC (0001108205) (Filer)
424B5 - CURIS INC (0001108205) (Filer)
4 - CURIS INC (0001108205) (Issuer)
4 - CURIS INC (0001108205) (Issuer)
4 - CURIS INC (0001108205) (Issuer)